2023
Comparison of the Revised 4 Th (2016) and 5 Th (2022) Editions of the World Health Organization (WHO) Classification in a Cohort of Patients with Lower-Risk Myelodysplastic Syndromes/Neoplasms (MDS) - a Glam Registry (REGLAM) Analysis
Iastrebner M, Zeidan A, Arbelbide J, Velloso E, Pereira T, Boada M, Crisp R, Pereyra P, Reyes J, Zappa M, perez-Jacobo F, Dela Peña Celaya J, Moreno E, Abello V, Solano M, Cuervo D, Espinosa D, Casas C, Montoya L, Enrico A, Prates V, Chavez E, Ontiveros-Austria J, Kornblihtt L, Leon A, Toledo V, Negri L, Serrano J, Sánchez A, Rodriguez-Zuñiga A, Stevenazzi M, Goldschmidt V, Grille S. Comparison of the Revised 4 Th (2016) and 5 Th (2022) Editions of the World Health Organization (WHO) Classification in a Cohort of Patients with Lower-Risk Myelodysplastic Syndromes/Neoplasms (MDS) - a Glam Registry (REGLAM) Analysis. Blood 2023, 142: 5179. DOI: 10.1182/blood-2023-185122.Peer-Reviewed Original ResearchProgression-free survivalTime of diagnosisAcute myeloid leukemiaMDS-MLDOverall survivalMDS patientsMDS-RSInternational Prognostic Scoring SystemLow-risk MDS patientsWorld Health Organization classificationLR-MDS patientsMedian blast countRisk MDS patientsCohort of patientsKaplan-Meier methodPrognostic scoring systemClassification of patientsNon-Hispanic whitesMDS-EB2PFS probabilityWHO 2016Baseline characteristicsBlast countMedian ageMeier method
2017
Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population‐based study
Zeidan AM, Hu X, Long JB, Wang R, Ma X, Podoltsev NA, Huntington SF, Gore SD, Davidoff AJ. Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population‐based study. Cancer 2017, 123: 3754-3762. PMID: 28621841, PMCID: PMC6540984, DOI: 10.1002/cncr.30814.Peer-Reviewed Original ResearchConceptsChronic myelomonocytic leukemiaRisk of deathSupportive careEnd Results-Medicare databaseOlder adultsMedian OS timeOverall survival benefitCohort of patientsProportional hazards modelUse of HMAsMedian OSAgent therapySurvival benefitOS timeCMML patientsMyelomonocytic leukemiaHazards modelHMA treatmentPatientsTemporal improvementSecondary analysisPropensity scoreLimited evidenceSurvival changesApproval
2013
P-124 Application of the French Prognostic Score to assess overall survival in a US-based cohort of patients treated with azacitidine
Zeidan A, Zhuoxin S, Prebet T, Greenberg P, Juckett M, Smith M, Paietta E, Gabrilove J, Erba H, Gore S, Tallman M. P-124 Application of the French Prognostic Score to assess overall survival in a US-based cohort of patients treated with azacitidine. Leukemia Research 2013, 37: s79-s80. DOI: 10.1016/s0145-2126(13)70172-3.Peer-Reviewed Original Research